KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Total Debt: 2017-2025

Historic Total Debt for Aquestive Therapeutics (AQST) over the last 8 years, with Sep 2025 value amounting to $36.3 million.

  • Aquestive Therapeutics' Total Debt rose 15.95% to $36.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $144.2 million, marking a year-over-year increase of 361.09%. This contributed to the annual value of $32.5 million for FY2024, which is 18.15% up from last year.
  • Aquestive Therapeutics' Total Debt amounted to $36.3 million in Q3 2025, which was up 3.56% from $35.0 million recorded in Q2 2025.
  • Over the past 5 years, Aquestive Therapeutics' Total Debt peaked at $54.2 million during Q1 2022, and registered a low of $27.5 million during Q4 2023.
  • Moreover, its 3-year median value for Total Debt was $33.8 million (2025), whereas its average is $34.2 million.
  • In the last 5 years, Aquestive Therapeutics' Total Debt spiked by 45.18% in 2021 and then slumped by 47.21% in 2023.
  • Over the past 5 years, Aquestive Therapeutics' Total Debt (Quarterly) stood at $53.6 million in 2021, then declined by 2.67% to $52.1 million in 2022, then slumped by 47.21% to $27.5 million in 2023, then climbed by 18.15% to $32.5 million in 2024, then increased by 15.95% to $36.3 million in 2025.
  • Its Total Debt stands at $36.3 million for Q3 2025, versus $35.0 million for Q2 2025 and $33.8 million for Q1 2025.